We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners

Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners

Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners

Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Allied-Bristol Life Sciences, LLC has announced that it has formed a strategic partnership with Synergy Partners R&D Solutions, LLC.

Synergy Partners, co-founded by Catherine D. Strader, Ph.D. and James S. MacDonald, Ph.D., comprises a network of over 20 well-respected experts that collectively have taken more than 100 drugs from discovery through development.

Their team of scientists offers expertise in areas such as disease biology, medicinal chemistry, process chemistry, toxicology, pharmacology and drug safety, and have proven track records at many of the world’s leading biopharmaceutical companies, including Bristol-Myers Squibb, Merck & Co., AstraZeneca, Pfizer Inc., Johnson & Johnson and Eli Lilly & Co.

This collective expertise offers essential insights for Allied-Bristol Life Sciences’ efforts to identify the most promising early-stage therapeutic opportunities at leading U.S. academic research institutions, and transform them into robust pre-clinical candidates for follow-on clinical development.

“The drug development team at Synergy Partners includes leaders within the biopharmaceutical industry in diseases of high interest to Allied-Bristol Life Sciences. We are pleased to have them joining our team as we move forward with this unique opportunity to advance academic innovations to drug candidates,” said Chris Silva, Chief Executive Officer of Allied Minds.

Allied-Bristol Life Sciences was formed earlier this year to identify discoveries from academic labs with promising therapeutic and commercial potential, and to drive these early-stage innovations from initial feasibility to pre-clinical candidacy. Synergy Partners will assist these efforts by lending strategic insights and decades of experience in the development, execution, and management of critical experiments and achievement of key milestones needed to successfully advance each research program.

“We are excited by the opportunity to work with Allied-Bristol Life Sciences to build a portfolio of novel and differentiated pre-clinical candidates,” said Synergy Partners’ Strader. “Synergy Partners is committed to bringing innovative new medicines to patients and Allied-Bristol Life Sciences offers a terrific model for optimizing innovation in the world of biopharmaceuticals.”